Twenty-four–Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes – Protocol 3 with High Dose (READ-3) Study - Sepah, Yasir J.; Sadiq, Mohammad Ali; Boyer, David; Callanan, David; Gallemore, Ron; Bennett, Michael; Marcus, Dennis; Halperin, Lawrence; Hassan, Muhammad; Campochiaro, Peter A.; Nguyen, Quan Dong; Do, Diana V.; et al. (Ophthalmology (Rochester, Minn.), 2016)
Keywords: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - adverse effects; Diabetic Retinopathy - drug therapy; Diabetic Retinopathy - physiopathology; Double-Blind Method; Female; Follow-Up Studies; Humans; Intravitreal Injections; Macula Lutea - drug effects; Macular Edema - drug therapy; Macular Edema - physiopathology; Male; Middle Aged; Ophthalmology; Ranibizumab - administration & dosage; Ranibizumab - adverse effects; Retreatment; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity - drug effects; Visual Acuity - physiology; OCT; SD OCT; FDA; READ-3; ETDRS; VEGF; TD-OCT; RBZ; VA; PRN; CFT; BCVA; DME; optical coherence tomography; ranibizumab; pro re nata; Food and Drug Administration; diabetic macular edema; Ranibizumab for Edema of the mAcula in Diabetes – Protocol 3 with High Dose; visual acuity; spectral-domain optical coherence tomography; central foveal thickness; time-domain optical coherence tomography; Early Treatment Diabetic Retinopathy Study; vascular endothelial growth factor; best-corrected visual acuity